• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clinical Data to Present at Drug Discovery Technology

Posted on: Tuesday, 8 August 2006, 12:01 CDT

Clinical Data, Inc. (NASDAQ: CLDA) today announced that two of its researchers will independently present at the upcoming Drug Discovery Technology and Development 11th Annual World Congress in Boston, Mass.

On Thursday, August 10, Benjamin A. Salisbury, Ph.D., Senior Director, Genetics and Biostatistics, will present on "Discovery of Biomarkers for a Rare Adverse Drug Reaction" at 2:00 PM ET. In Dr. Salisbury's presentation, data will be presented on the Company's successful studies on Clozapine-Induced Agranulocytosis (CIA) in which a genetic marker predictive of CIA was discovered and then replicated. Applicability of the approach taken to developing genetic tests predictive of other rare adverse events will also be discussed. The data from the study was derived from Clinical Data's Clozapine and Agranulocytosis Relationships Induced by Genetic Variants ("CARING") study.

On Wednesday, August 9, Alan Higgins, Ph.D., Senior Director, Investigational Medicine, will present on "Multi-Omic Markers of Acute and Chronic Liver Injury" at 2:50 PM ET. This talk will describe a study of liver injury produced by several chemical toxicants in which metabolomic and microarray data were combined using multivariate statistics to identify biomarkers and pathways involved in liver toxicity.

The Company has previously announced it is developing a commercial genetic test for CIA risk using its newly validated research and noted that its research team continues to work on identifying and validating other genetic markers in this and other areas. PGxHealth's new clozapine test will provide physicians, patients and their families with new, quantifiable information about a patient's risk for CIA and should lead to better informed treatment decisions concerning initiating or continuing treatment of schizophrenia with clozapine.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. The Company, founded in 1972, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM); Cogenics(TM); and Vital Diagnostics(TM). Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in some instances in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data currently employs a staff of over 430. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, RTP - North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia. Furthermore, Clinical Data has numerous distribution, licensing, development and other collaborations with key partners.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005 and 2006 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com

Source: Business Wire

More News in this Category